Logos, the Greek word for logic and discourse, emphasizes our philosophy of seeking empirical truth and rigorous scientific diligence across our investment endeavors.
Seeking Logos
Logos Capital is a fundamental biotechnology-focused investment partnership that combines scientific and financial expertise with in-house clinical trial analytics to identify transformative therapies in healthcare. Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment themes and opportunities.
Our Mission
Build a world-class biotechnology investment partnership, focused on generating superior long-term returns for our investors and financing innovation that will meaningfully advance the standard of care for patients
Success in drug development is contingent on more than just scientific research. Our process focuses on event tracking, clinical trial underwriting, risk management, and a culture rooted in technical diligence and continuous improvement. We seek to holistically assess an asset from its preclinical data through commercialization potential to determine intrinsic value.
Identify
We rigorously track and diligence all private and public companies in our sector, looking for best in class or first in class companies with attractive valuations.
Invest
New technologies and therapeutic approaches are leading to functional cures, expanding patient access, extending life expectancy and redefining the meaning of ‘value.’ We continually screen for opportunities that are clear advances to the current treatment paradigm and standard of care.
Deliver Value
Our mandate is to deliver best-in-class returns to our investors. To do so, we thoroughly underwrite each investment, incorporating multiple layers of risk management to ensure our rationale, our “logos”, is perpetually aligned with those supporting us.
Team
The Logos team is composed of trained experts in the field of chemistry, engineering, biology, and data science. We are committed to supporting true innovation through investing directly in companies pushing the boundaries of medical science and patient care.
Investment
Dr. Arsani William, MD, MBA
Prior to founding Logos, Dr. William was an investment professional at Farallon Capital Management, where he grew Farallon’s biopharma portfolio.
Dr. William holds an MD from Harvard Medical School, where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.
Dr. William currently serves on the board of Design Therapeutics (NASDAQ: DSGN) and is a board observer on Odyssey Therapeutics.
Managing Partner /
Chief Investment Officer
Dr. Graham Walmsley, MD, PhD
Prior to co-founding Logos, Dr. Walmsley was a Principal and Portfolio Manager of the Vantage crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director while building and launching multiple companies, including BlueRock Therapeutics (acquired by Bayer AG) and Akero Therapeutics. He was also the head of business development for Jecure Therapeutics through its acquisition by Genentech, a subsidiary of Roche.
Dr. Walmsley has authored more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.
Dr. Walmsley currently serves on the board of Akero Therapeutics (NASDAQ: AKRO) and Olema Pharmaceuticals (NASDAQ: OLMA).
General Partner
Dr. Ed Zhong, PhD
Prior to Logos, Dr. Zhong was the founding data scientist at Farallon Capital Management, where he helped lead the development of clinical trial models, analysis of large datasets, and antitrust models for M&A situations.
Ed holds a BA in Economics from Harvard University and a PhD in Economics from the University of Wisconsin-Madison.
General Partner
Dr. Yuqi Wang, PhD
Prior to Logos, Yuqi held academic research and analytics positions at Yale University, Pecking University, University of Oxford, and Pennsylvania State University. Yuqi holds a BS in Basic Medical Sciences from Peking University and a PhD in Biomedical Engineering from Yale University. His dissertation was on the functional and molecular mechanisms of stem cells.
Analyst
Operations
Derek Gould, JD
Prior to Logos, Derek was the General Counsel and Chief Compliance Officer at Figment Capital, an emerging venture fund. Previously, Derek served as Chief Compliance Officer and Counsel at SRS Investment Management, a tech focused hedge fund with more than $7B under management. Prior to SRS, he held roles at Folger Hill Asset Management and Apollo Global Management.
Derek holds a BS of Engineering from the University of Michigan and a JD from the Benjamin N. Cardozo School of Law.
General Counsel /
Chief Compliance Officer
Cynthia (Cindy) Goldsmith, CPA
Prior to joining Logos, she was the Chief Financial Officer at Asymmetry Capital Management, where she was responsible for all financial activities of the Management Company as well as financial management and reporting for funds under management. Previously, Cindy was the Manager of Hedge Fund Administration and Accounting Manager at Forward Management, the Controller of Kensington Investment Group (acquired by Forward), where she was responsible for the accounting, taxes and administration of over 10 hedge funds.
Cindy is a Certified Public accountant and holds a B.S. in Accounting from the University of California, Berkeley.
Chief Financial Officer
Udit Dalal
Prior to Logos, Udit was Vice President at Goldman Sachs Prime Brokerage and was responsible for managing client relationships and providing overall operational support to several prominent CA hedge funds. Previous to Goldman Sachs, Udit had various similar roles in the investment management business as well as at Morgan Stanley Prime Brokerage in New York.
Udit holds an MBA degree from the LeBow School of Business at Drexel University and an undergraduate degree from University of Mumbai.
VP, Operations
Elana Sears
Prior to Logos, Elana oversaw BTIG’s West Coast Capital Introduction efforts. Previously, she spent 7 years at PJT Park Hill as a Director on the Private Credit & Hedge Fund team. Elana began her career at Morgan Stanley as a Capital Introduction Analyst.
Elana holds a BS with honors in International Business / Human & Organizational Development from Vanderbilt University.
Head of Marketing & Investor Relations
Bonny Chen
Prior to Logos, she was the Executive Assistant to the Partner, CFO/COO and the Director of Legal Affairs and supported the internal operations team at 137 Ventures. Previously, Bonny has supported various C-suite executives in the financial industry, ranging from real estate investments to venture capital.
Bonny holds a B.A. in Sociology and Business Administration with a focus in marketing from the University of California, Riverside.
Senior Lead, Marketing and Operations
Eileen O'Donoghue
Prior to Logos, Eileen was an executive assistant to the fintech and product strategy team for the Commercial Bank at JPMorgan. Eileen began her administrative career in the hospitality and events sector supporting various sales and marketing teams.
Eileen holds a BA in Business and Event Management from Limerick Institute of Technology, Ireland.
Executive Assistant and Office Manager
View All
Dr. Arsani William, MD, MBA
Prior to founding Logos, Dr. William was an investment professional at Farallon Capital Management, where he grew Farallon’s biopharma portfolio.
Dr. William holds an MD from Harvard Medical School, where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.
Dr. William currently serves on the board of Design Therapeutics (NASDAQ: DSGN) and is a board observer on Odyssey Therapeutics.
Managing Partner /
Chief Investment Officer
Dr. Graham Walmsley, MD, PhD
Prior to co-founding Logos, Dr. Walmsley was a Principal and Portfolio Manager of the Vantage crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director while building and launching multiple companies, including BlueRock Therapeutics (acquired by Bayer AG) and Akero Therapeutics. He was also the head of business development for Jecure Therapeutics through its acquisition by Genentech, a subsidiary of Roche.
Dr. Walmsley has authored more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.
Dr. Walmsley currently serves on the board of Akero Therapeutics (NASDAQ: AKRO) and Olema Pharmaceuticals (NASDAQ: OLMA).
General Partner
Dr. Ed Zhong, PhD
Prior to Logos, Dr. Zhong was the founding data scientist at Farallon Capital Management, where he helped lead the development of clinical trial models, analysis of large datasets, and antitrust models for M&A situations.
Ed holds a BA in Economics from Harvard University and a PhD in Economics from the University of Wisconsin-Madison.
General Partner
Derek Gould, JD
Prior to Logos, Derek was the General Counsel and Chief Compliance Officer at Figment Capital, an emerging venture fund. Previously, Derek served as Chief Compliance Officer and Counsel at SRS Investment Management, a tech focused hedge fund with more than $7B under management. Prior to SRS, he held roles at Folger Hill Asset Management and Apollo Global Management.
Derek holds a BS of Engineering from the University of Michigan and a JD from the Benjamin N. Cardozo School of Law.
General Counsel /
Chief Compliance Officer
Cynthia (Cindy) Goldsmith, CPA
Prior to joining Logos, she was the Chief Financial Officer at Asymmetry Capital Management, where she was responsible for all financial activities of the Management Company as well as financial management and reporting for funds under management. Previously, Cindy was the Manager of Hedge Fund Administration and Accounting Manager at Forward Management, the Controller of Kensington Investment Group (acquired by Forward), where she was responsible for the accounting, taxes and administration of over 10 hedge funds.
Cindy is a Certified Public accountant and holds a B.S. in Accounting from the University of California, Berkeley.
Chief Financial Officer
Elana Sears
Prior to Logos, Elana oversaw BTIG’s West Coast Capital Introduction efforts. Previously, she spent 7 years at PJT Park Hill as a Director on the Private Credit & Hedge Fund team. Elana began her career at Morgan Stanley as a Capital Introduction Analyst.
Elana holds a BS with honors in International Business / Human & Organizational Development from Vanderbilt University.
Head of Marketing & Investor Relations
Dr. Yuqi Wang, PhD
Prior to Logos, Yuqi held academic research and analytics positions at Yale University, Pecking University, University of Oxford, and Pennsylvania State University. Yuqi holds a BS in Basic Medical Sciences from Peking University and a PhD in Biomedical Engineering from Yale University. His dissertation was on the functional and molecular mechanisms of stem cells.
Analyst
Udit Dalal
Prior to Logos, Udit was Vice President at Goldman Sachs Prime Brokerage and was responsible for managing client relationships and providing overall operational support to several prominent CA hedge funds. Previous to Goldman Sachs, Udit had various similar roles in the investment management business as well as at Morgan Stanley Prime Brokerage in New York.
Udit holds an MBA degree from the LeBow School of Business at Drexel University and an undergraduate degree from University of Mumbai.
VP, Operations
Elana Sears
Prior to Logos, Elana oversaw BTIG’s West Coast Capital Introduction efforts. Previously, she spent 7 years at PJT Park Hill as a Director on the Private Credit & Hedge Fund team. Elana began her career at Morgan Stanley as a Capital Introduction Analyst.
Elana holds a BS with honors in International Business / Human & Organizational Development from Vanderbilt University.
Head of Marketing & Investor Relations
Bonny Chen
Prior to Logos, she was the Executive Assistant to the Partner, CFO/COO and the Director of Legal Affairs and supported the internal operations team at 137 Ventures. Previously, Bonny has supported various C-suite executives in the financial industry, ranging from real estate investments to venture capital.
Bonny holds a B.A. in Sociology and Business Administration with a focus in marketing from the University of California, Riverside.
Senior Lead, Marketing and Operations
Eileen O'Donoghue
Prior to Logos, Eileen was an executive assistant to the fintech and product strategy team for the Commercial Bank at JPMorgan. Eileen began her administrative career in the hospitality and events sector supporting various sales and marketing teams.
Eileen holds a BA in Business and Event Management from Limerick Institute of Technology, Ireland.
Executive Assistant and Office Manager
Investments
858 THERAPEUTICS INC
Affinivax
Aligos Therapeutics
Aligos is developing targeted, curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B virus, non-alcoholic steatohepatitis and hepatocellular carcinoma.
ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system.
Annexon Biosciences
Annexon Biosciences is a pioneer in developing C1q inhibitors designed to treat multiple complement-medicated autoimmune and neurodegenerative diseases.
Athira Pharma
Athira Pharma is a clinical stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer's disease and Parkinson's disease.
Avidity Biosciences
Avidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.
Black Diamonds Therapeutics
Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule, Tumor-Agnostic Therapies
Biomea Fusion
Boundless BIO INC
C4 Therapeutics
C4 Therapeutics is committed to transforming the treatment of cancer, neurological, and other important diseases with novel early stage therapies that eliminate disease-causing proteins. C4’s approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients.
Centessa Pharmaceuticals
Century Therapeutics
Cogent Biosciences
Cogent Biosciences is a biotechnology company developing therapies for genetically driven diseases.
Cullinan Oncology
Day One Biopharmaceuticals
Design Therapeutics
Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.
Edgewise Therapeutics
Element Biosciences INC
Enliven Therapeutics
Flame Biosciences
Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.
Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
GH Research
Graphite Bio
IconOVir Bio
Ikena Oncology
InstilBio
Instil Bio is a cell therapy company focused on solid tumors developing patient specific immunotherapies in oncology, allowing the patient’s own immune system to be harnessed to fight cancer.
Interius
Janux
Kinnate Biopharma
Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities. Kinnate design and develop selective small molecules with the mission to provide the right drug to the right patient.
Kymera Therapeutics
Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases, advancing the field of targeted protein degradation by accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins.
LianBio
Nkarta Therapeutics
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
Nikang Therapeutics INC
Nuvalent INC
Olema Pharmaceuticals
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.
Passage Bio
Passage Bio is a genetic medicines company developing transformative therapies for the treatment of rare monogenic central nervous system diseases
Pliant Therapeutics
Pliant Therapeutics is a clinical stage biopharmaceutical company unraveling and targeting the key biological pathways driving fibrosis.
Quanta Therapeutics
No Website
Rain Therapeutics
Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer.
Rayze Bio
Repare Therapeutics
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.
Scorpion Therapeutics
Shoreline Biosciences
SomaLogic
Talaris Therapeutics
Talaris is developing a single-dose cell therapy that seeks to produce durable immune tolerance to both an individual’s own tissues as well as donated organs from another individual.
VelosBio
VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.
Ventyx Biosciences
Verve Therapeutics
Visen Pharmaceuticals
VISEN Pharmaceuticals is committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market, and hoping to provide more Chinese patients quick access to the world's most advanced and reliable treatment solutions. In 2018, VISEN Pharmaceuticals was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Investments), to develop and commercialize endocrinology therapies in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan.
Vividion Therapeutics
Willow
